



## TACO and TRALI: biology, risk factors, and prevention strategies

Nareg Roubinian

*Blood Systems Research Institute, San Francisco, CA; Kaiser Permanente Northern California Medical Center and Division of Research, Oakland, CA; and Department of Laboratory Medicine, University of California, San Francisco, CA*

**Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are the leading causes of transfusion-related morbidity and mortality. These adverse events are characterized by acute pulmonary edema within 6 hours of a blood transfusion and have historically been difficult to study due to underrecognition and nonspecific diagnostic criteria. However, in the past decade, in vivo models and clinical studies utilizing active surveillance have advanced our understanding of their epidemiology and pathogenesis. With the adoption of mitigation strategies and patient blood management, the incidence of TRALI and TACO has decreased. Continued research to prevent and treat these severe cardiopulmonary events is focused on both the blood component and the transfusion recipient.**

### Learning Objectives

- Review the definitions and pathophysiology of pulmonary transfusions incorporating recent in vivo models and clinical investigations
- Highlight transfusion and recipient risk factors for transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI) with an emphasis on patients with hematological malignancies
- Describe the contemporary incidence and prevention of TACO and TRALI in relation to mitigation strategies and patient blood management

2 consensus conferences convened more than a decade ago to standardize definitions of TRALI.<sup>6,14</sup> In parallel, working groups representing blood transfusion societies have endeavored to improve the criteria for TACO, recognizing that current surveillance definitions lacked specificity.<sup>15,16</sup> Accurate diagnosis of these reactions relies on interpretation of clinical, radiographic, and hemodynamic data that are labor intensive to extract and require expertise to interpret.<sup>17</sup> In this regard, research studies of TACO and TRALI frequently use a panel of expert clinicians with knowledge in both intensive care and transfusion medicine to adjudicate cases.<sup>1,9,18</sup>

Common to all pulmonary transfusion reactions is the development of acute pulmonary edema within 6 hours of blood transfusion—characterized by bilateral pulmonary opacities on chest radiography and hypoxemia by arterial blood gas or pulse oximetry testing ( $\text{PaO}_2/\text{FiO}_2 < 300$ ,  $\text{SpO}_2 < 90\%$  on room air, or other evidence of hypoxia). Surveillance definitions provide a framework for the identification and characterization of individual transfusion reactions that can be differentiated by the presence or absence of risk factors for acute respiratory distress syndrome (ARDS) and findings of circulatory overload (ie, findings of left atrial hypertension) (Table 1).<sup>17</sup> The Canadian Consensus Criteria defines TRALI as acute pulmonary edema after transfusion in the absence of circulatory overload or alternate ARDS risk factors. In contrast, possible TRALI is defined as above, except it includes a temporal association with an ARDS risk factor. TACO is pulmonary edema primarily related to circulatory overload with criteria developed by the National Healthcare Safety Network including 3 or more of the following within 6 hours of transfusion: acute respiratory distress, radiographic pulmonary edema, elevated central venous pressure, evidence of left heart failure, elevated B-type natriuretic peptide (BNP), and a positive fluid balance.

### Introduction

With a growing body of knowledge regarding their pathogenesis, pulmonary transfusion reactions are drawing attention as potentially preventable medical complications. Systematic data collection has played an important role in understanding the incidence and epidemiology of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO).<sup>1-6</sup> These often severe hazards of transfusion have been independently associated with morbidity and mortality and account for the majority of all transfusion-related deaths since 2011.<sup>7-10</sup> This report summarizes the current definitions, pathophysiology, and risk factors for TRALI and TACO, with additional focus on patients with hematological malignancies. In addition, we will review the impact of mitigation strategies and patient blood management (PBM) on reducing their incidence and role for further prevention.<sup>11</sup>

### Definitions

A lack of consensus regarding diagnostic criteria has hindered clinical recognition and research investigation of pulmonary transfusion reactions.<sup>12,13</sup> To promote more uniform reporting and research study,

Conflict-of-interest: N.R. has declared no competing financial interests.

Off-label drug use: None disclosed.

**Table 1. Characteristics of pulmonary transfusion reactions**

Characteristic	Possible		
	TRALI	TRALI	TACO
Bilateral infiltrates on chest radiograph consistent with acute pulmonary edema	Yes	Yes	Yes
Evidence of hypoxemia*	Yes	Yes	Yes
Evidence of circulatory overload†	No	Yes/no	Yes
Presence of major ARDS risk factor(s)‡	No	Yes	No

\*Hypoxemia defined as PaO<sub>2</sub>/FiO<sub>2</sub> < 300, SpO<sub>2</sub> < 90% on room air, or other evidence of hypoxia.

†A systematic evaluation of echocardiography (ejection fraction, diastolic function, and ventricular filling pressures), chest radiography (cardiothoracic ratio and vascular pedicle width), laboratory findings (B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide), hemodynamic parameters (systolic blood pressure and central venous pressure), and clinical course (rapid resolution of pulmonary edema after preload reduction favoring a hydrostatic rather than permeability etiology).

‡Major ARDS risk factors included pneumonia, sepsis, aspiration, multiple fractures, and pancreatitis.

### Clinical presentation

Signs and symptoms of TACO and TRALI begin within 6 hours of completion of blood transfusion and include tachycardia, tachypnea, and hypoxia. These clinical findings can be blunted, particularly in postoperative or intensive care patients who may not exhibit signs of respiratory distress due to sedation or preexisting ventilatory support. Cardiovascular risk factors predominate in TACO; patients tend to be older and frequently have a history of congestive heart failure and/or coronary artery disease (Table 2).<sup>2,3</sup> Renal impairment as reflected by a history of chronic kidney disease is also common in TACO, whereas acute kidney disease and liver failure are prevalent in both TRALI and possible TRALI.<sup>2,5,19</sup> Surgery (both emergency or elective) is frequently associated with TACO and TRALI, with >1/2 of cases of each occurring perioperatively.<sup>2,5,20</sup> TRALI and possible TRALI have also been associated with chronic alcohol abuse, tobacco use, shock before transfusion, and a positive fluid balance relative to

transfused controls.<sup>1,21,22</sup> Although hypertension can occur with TACO, shock is common in TACO, TRALI, and possible TRALI, with ~1/2 of cases requiring concurrent vasopressor support in one series.<sup>20</sup>

BNP testing has had a major impact on the diagnosis and management of patients with pulmonary edema—including those with TACO and TRALI.<sup>23,24</sup> BNP levels classically are elevated in patients with congestive heart failure or circulatory overload. However, elevated BNP levels have also been reported in clinical trials of ARDS, in which almost 1/3 of cases had pulmonary capillary wedge pressure measurements consistent with concomitant hydrostatic edema.<sup>25,26</sup> In addition to volume overload, BNP is thought to be elevated through other mechanisms related to cardiac stress, such as catecholamine release or hypoxia.<sup>25</sup> Initial studies in transfusion found elevated BNP levels in patients with TACO compared with transfused controls.<sup>27,28</sup> Subsequent studies found higher BNP levels in cases of TACO and possible TRALI relative to cases of TRALI.<sup>29-31</sup> Indeed, BNP levels were similar in TACO and possible TRALI, suggesting practical utility in their differentiation from TRALI.

Echocardiography can also provide critical information regarding the pathogenesis of pulmonary edema after transfusion and has supplanted invasive hemodynamic monitoring in this regard.<sup>3,26,32</sup> Echocardiography offers a noninvasive structural and functional cardiac assessment and often reveals findings that had been unrecognized clinically.<sup>8,33</sup> Evidence of elevated cardiac filling pressures or systolic and/or diastolic dysfunction suggest circulatory overload and a diagnosis of TACO in the setting of pulmonary edema.<sup>3</sup> In contrast, the absence of echocardiographic abnormalities is central to the diagnosis of TRALI, and elevations in BNP are less frequent. In the setting of risk factors for ARDS, cases of possible TRALI may have findings of cardiac dysfunction and elevated filling pressures, supporting both a permeability and hydrostatic basis for pulmonary edema.<sup>20</sup>

**Table 2. Characteristics of cases and transfused controls from the TRALI Specialized Clinical Center for Outcomes Research**

Patient characteristic	TRALI, n = 89	Possible TRALI, n = 130	TACO, n = 83	Control, n = 164
Units transfused*	4 (2-13)	3 (2-5)	4 (2-10)	3 (2-10)
Blood component type				
Red blood cells	67 (75%)	83 (64%)	66 (80%)	127 (77%)
Plasma	59 (66%)	70 (54%)	46 (55%)	81 (49%)
Platelets	37 (42%)	52 (40%)	43 (52%)	56 (34%)
Comorbid characteristics				
History of congestive heart failure	7 (8%)	8 (6%)	29 (35%)	13 (8%)
Coronary artery disease	15 (17%)	31 (24%)	34 (41%)	30 (18%)
Acute renal failure	23 (26%)	34 (26%)	15 (18%)	17 (10%)
Chronic renal failure	5 (6%)	11 (12%)	15 (18%)	14 (9%)
Severe liver disease	21 (24%)	20 (15%)	9 (11%)	15 (9%)
Chronic alcohol abuse	12 (13%)	17 (13%)	5 (6%)	6 (4%)
History of tobacco use	18 (20%)	27 (21%)	11 (13%)	18 (11%)
Hematologic malignancy	6 (7%)	25 (19%)	6 (7%)	30 (18%)
Recent surgery	54 (61%)	49 (38%)	62 (75%)	68 (41%)
Clinical characteristics				
Shock before transfusion	39 (44%)	59 (45%)	32 (39%)	30 (18%)
Ventilation after transfusion	42 (47%)	68 (52%)	56 (67%)	39 (24%)
Fluid balance, L	3.7 (1.6-7.3)	4.5 (1.7-7.7)	3.7 (1.6-6)	2.0 (0.4-4.5)
BNP after transfusion, pg/mL†	252 (133-593)	693 (361-1370)	1907 (1108-2339)	373 (291-589)

Subjects are from the TRALI Specialized Clinical Center for Outcomes Research study (from 2006 to 2009).<sup>1</sup> Data are reported as median values (interquartile ranges) or numbers (percentages).

\*Number of blood components transfused in the 6 hours before development of pulmonary edema for cases.

†This is a subset of the total BNP after transfusion (n = 98), pg/mL.

Transfusion-specific risk factors for TRALI and TACO include the total number of blood products administered, regardless of component type.<sup>1</sup> Plasma from a previously pregnant blood donor is a well-established risk factor for TRALI due to pregnancy-related alloimmunization (ie, development of antileukocyte antibodies).<sup>1,34-37</sup> One study assessed the prevalence of human leukocyte antigen (HLA) antibodies in female donors using flow cytometry and found a dose-response increase in HLA antibodies with the number of prior pregnancies.<sup>38,39</sup> Although blood components with a high volume of plasma (eg, plasma, apheresis platelet concentrates, and whole blood) have been shown to confer the highest risk, TRALI has been reported after all products—including cryoprecipitate, granulocytes, intravenous immunoglobulin preparations, and stem cell products.<sup>40-42</sup> For TACO, the independent association with plasma transfusion is seemingly related to the large volume of multiple blood products required to reverse coagulopathy in patients with impaired cardiac and renal function.<sup>3,5,9</sup>

Patients with hematologic malignancies would seem to be at increased risk of TACO and TRALI. Patients receiving chemotherapy or undergoing hematopoietic stem cell transplantation require frequent blood transfusions in addition to significant volumes of maintenance fluids, parenteral nutrition, and intravenous medications. In addition, lymphoma and leukemia are common in older individuals who often have preexisting cardiovascular disease and are more prone to chemotherapy-induced cardiac dysfunction or kidney injury, risk factors for TACO. Severe thrombocytopenia occurs commonly in patients receiving treatment of leukemia, and frequent platelet and red blood cell (RBC) transfusions are often required. Indeed, pulmonary reactions in patients with leukemia and lymphoma tend to be associated with fewer transfusions per case and more frequent platelet transfusion compared with other populations (Tables 2 and 3).<sup>1,19</sup> However, there are no clear differences in component type or platelet and leukocyte counts compared with transfused controls with leukemia or lymphoma, although observations are limited by small sample sizes. Despite these risk factors, TACO and TRALI occur less frequently in patients with hematologic malignancy relative to transfused controls. Although TRALI can develop through direct activation of the pulmonary endothelium, the lower incidence of TRALI in leukemia and lymphoma patients is likely related to neutropenia (see below).<sup>43</sup>

**Table 3. Transfusion characteristics of TRALI Specialized Clinical Center for Outcomes Research subjects with leukemia or lymphoma**

Characteristic	Possible			
	TRALI, n = 6	TRALI, n = 25	TACO, n = 6	Controls, n = 30
Total cases, %	7 (6/89)	19 (25/130)	7 (6/83)	18 (30/164)
Units transfused	1 (1-1)	1 (1-2)	1 (1-2)	2.5 (2-3)
RBCs, %	50	32	33	73
Platelets, %	67	72	83	63
Plasma, %	0	24	0	17
Laboratory results				
WBC count	1.7 (0.2-2.4)	3.1 (0.2-10.5)	3.6 (0.1-6.9)	1.6 (0.2-4.6)
Platelet count	24 (5-33)	25 (12-45)	43 (17-73)	22 (11-35)

Subjects are from the TRALI Specialized Clinical Center for Outcomes Research study.<sup>1</sup> Data are reported as median values (interquartile ranges) or numbers (percentages). WBC, white blood cell.

Alternative causes of lung injury also need to be considered in patients with hematologic malignancies requiring blood transfusions. Lung injury related to sepsis or pneumonia is a common adverse event in the treatment of hematologic malignancies. Other noninfectious pulmonary complications include drug- or chemotherapy-induced pneumonitis, organizing pneumonia, diffuse alveolar hemorrhage, and idiopathic pulmonary syndromes; the latter is an infrequent albeit severe early complication of hematopoietic stem cell transplantation that may occur during a period of increased transfusion requirement. In general, pulmonary edema due to TACO and TRALI tends to be less severe and is associated with lower mortality compared with that in patients with ARDS and the above complication syndromes.<sup>2,21,22</sup>

## Incidence

Historically, incidence estimates of TACO and TRALI have been based on adverse event reporting by national hemovigilance systems. The major limitation of these systems is reliance on passive reporting of transfusion reactions, which is known to underestimate true incidence given poor syndrome recognition.<sup>12,44,45</sup> Expanded use and versatility of electronic health records (EHRs) have helped to address this limitation by incorporating algorithms that screen transfused patients for signs suggestive of pulmonary transfusion reactions. Active surveillance improves accuracy of assessment and reporting, thus offering a better approximation of the epidemiology of these reactions.<sup>1,5,13,46</sup> As an example, the largest active surveillance study of TRALI used an electronic screening algorithm, the collection of granular clinical data, and expert panel review for outcome adjudication in a multicenter population of both medical and surgical patients. Collectively, this served to more definitively correlate the type and strength of HLA antibodies with TRALI and showed a clear decline in TRALI incidence after plasma mitigation.<sup>1</sup>

Reported incidence rates of TACO and TRALI have varied based on the studied patient population or component type. Historically, active surveillance estimates of TRALI were ~0.1% of transfused patients but up to 5% to 8% in groups of intensive care unit populations.<sup>4,19,42</sup> Classification of possible TRALI with ARDS risk factors and TRALI cases together accounts for some of the variability in reported incidence in hemovigilance and active surveillance studies.<sup>4,19,29,42,47</sup> Prospective studies of TRALI in diverse, multicenter populations found lower incidence rates (0.0008% to 0.001% of transfused patients) after implementation of donor mitigation strategies.<sup>1,9</sup> In parallel to studies of TRALI, case series have reported higher TACO incidence related to plasma transfusion and in perioperative or critically ill populations (1% to 4% of transfused patients).<sup>2,5,19,48</sup> After declines in transfusion related to PBM, TACO has been estimated to occur in ~1% of transfused patients.<sup>9,13</sup>

## Pathophysiology

### Antibody-mediated TRALI

Murine models and human studies support an antibody-mediated basis for TRALI. Donor leukocyte antibodies present in the plasma of a transfused blood component are postulated to bind to cognate (ie, corresponding) antigen in the recipient, resulting in capillary leak and lung injury. This hypothesis is supported by in vivo models, in which TRALI develops after antibodies to HLA or human neutrophil antigen (HNA) are infused into animals expressing cognate antigens.<sup>49-51</sup> The demonstration of antibodies in blood donor plasma with specificities or cross-reactivity against cognate recipient antigens (ie, recipient HLA type or HNA) provides additional evidence for this hypothesis.<sup>1,44,52,53</sup>

However, the majority of transfused blood products that contain HLA antibodies do not cause TRALI, even when a cognate recipient antigen is present.<sup>38</sup> In one study, TRALI occurred in only 3% of recipients who received blood products from donors that had previously been implicated in cases of TRALI.<sup>54</sup> It was hypothesized that TRALI induction required sufficient quantity of antibody as determined by the volume of plasma transfused as well as the antibody class and strength (threshold hypothesis). In a multivariable analysis, the strength of cognate HLA class 2 antibody and the volume of HNA antibody were strong predictors of TRALI, with less evidence supporting the role of HLA class 1 antibodies.<sup>1,55</sup> However, all classes of cognate antibody exposure have been associated with severe and fatal cases of TRALI.<sup>56</sup>

In addition to cognate antibody exposure, systemic inflammation in the transfusion recipient is thought to be critical to TRALI pathogenesis by priming neutrophils and activating pulmonary endothelial cells.<sup>57-59</sup> The role of pretransfusion inflammation as part of a “2-event hypothesis” is supported by murine models of TRALI, in which an inflammatory response related to lipopolysaccharide or other stimuli (first event) is often required for HLA antigen/antibody interactions (second event) to induce lung injury.<sup>50,60</sup> Elevations in inflammatory cytokines interleukin-6 (IL-6), IL-8, and C-reactive protein before transfusion have been associated with the development of TRALI; the latter was also shown to enhance TRALI when administered in a murine model.<sup>20,61-63</sup> Systemic inflammation induces the expression of adhesion molecules on endothelial cells (CD62, ICAM-1) and neutrophils (PSGL-1), increasing interaction with peripheral granulocytes and resulting in intrapulmonary leukostasis.

In the setting of a systemic inflammatory process, recipient neutrophils are then activated by a sufficient quantity of cognate antibody in a transfused blood component. Neutrophil activation is associated with the release of inflammatory cytokines, reactive oxygen species, oxidases, proteases, and neutrophil extracellular traps that disrupt the alveolar-capillary barrier of the lung, resulting in an inflammatory form of pulmonary edema.<sup>58,64,65</sup> Endothelial cell activation in areas of neutrophil aggregation in lung tissue is evidenced by high expression of adhesion molecules, such as CD31 and CD34, by immunohistochemistry.<sup>66</sup> In some models, lung injury is dependent on neutrophil expression of Fc  $\gamma$ -receptors, and it is interdicted in mice through depletion of neutrophils using anti-granulocyte antibodies.<sup>67</sup> A supportive role for neutrophils in TRALI is further provided by the detection of neutrophil extracellular traps in both TRALI experimental models and human samples as well as the alleviation of lung injury by blocking neutrophil extracellular traps.<sup>64,65</sup> In a small number of human cases, initiation of TRALI was thought to be reversed, with a leukoagglutinating antibody present in the recipient reacting to HLA antigens on the surface of transfused neutrophils, so-called “reverse TRALI.”<sup>40,68</sup>

There are supportive data on the role of other effector cells in TRALI in addition to neutrophils. Donor antileukocyte antibodies can also bind to antigens on monocytes and macrophages (HLA class 2 antibody), pulmonary endothelial cells, and platelets (HLA class 1 antibodies); these mechanisms may play a role in the development of TRALI in the setting of neutropenia (eg, patients with hematologic malignancy). For example, one lipopolysaccharide-dependent murine model found that HLA class 1 antibodies bound the vascular endothelium, resulting in complement and monocyte activation and subsequent damage to the pulmonary endothelium by reactive oxygen

species.<sup>43</sup> Other lipopolysaccharide-dependent and -independent murine models have found antibody binding of monocytes or the pulmonary endothelium, but they have also involved neutrophilic pulmonary infiltration in the development of TRALI.<sup>69,70</sup>

In parallel, platelets may play a role in TRALI pathogenesis, secreting proinflammatory mediators and interacting directly with neutrophils to promote their activation.<sup>64</sup> Platelet migration into the alveolar spaces occurs in murine models of TRALI either alone or complexed with neutrophils. It is clear that differences in murine genotype, method of platelet depletion, and need for lipopolysaccharide explain some of the differences in proposed TRALI mechanisms as well as those between animal models and TRALI in humans. Additional investigations are needed to resolve these differences and advance our understanding of TRALI pathogenesis.

#### *Nonantibody-mediated TRALI*

In ~20% of TRALI cases, HLA and HNA antibodies are not identified in the transfused product, despite the use of sensitive assays.<sup>71,72</sup> These cases of “nonantibody-mediated” TRALI may be due to unidentified antibodies or exposure to other biological reactive molecules (BRMs) within the transfused blood component administered. In parallel to donor leukocyte antibodies in the 2-event hypothesis for antibody-mediated TRALI, BRMs are thought to be the necessary stimuli to trigger the cascade of lung injury in a primed transfusion recipient. Cases of TRALI associated with RBC transfusion are infrequently associated with antileukocyte antibodies; instead, inflammatory factors in the supernatant of RBCs are thought to play a role in the pathogenesis in these cases. The contribution of inflammatory mediators to development of nonimmune TRALI is partially supported by retrospective, observational data showing a decline in the incidence of TRALI after universal leukoreduction.<sup>73,74</sup> However, *in vitro* evidence showing accumulation of leukocyte-derived inflammatory cytokines, soluble CD40 ligand, and nonpolar lipids (lysophosphatidylcholines) with prolonged RBC and platelet storage is not supported by case-control studies of human TRALI.<sup>1,42,75-80</sup> Ongoing research of nonantibody-mediated TRALI is focused on the role of blood donor characteristics and component manufacturing methods.<sup>81,82</sup>

#### *Possible TRALI*

The role of transfusion in the development or exacerbation of lung injury in patients with ARDS risk factors (eg, sepsis or pneumonia) remains a topic of debate.<sup>83</sup> Infectious risk factors for ARDS are common in patients with hematologic malignancy, further complicating distinction. Nonetheless, the high mortality associated with pulmonary edema requiring invasive mechanical ventilation in immunocompromised patients underscores the need to understand transfusion’s contribution to ARDS in this frequently transfused population.<sup>84,85</sup>

The pathogenesis and clinical course of possible TRALI are very different from those of antibody-mediated TRALI.<sup>21,22</sup> Pretransfusion elevations in inflammatory cytokine, such as IL-8, are prominent, but antileukocyte antibodies are infrequent in possible TRALI.<sup>22,34</sup> Research of biologic response mediators in possible TRALI has focused on the storage age of blood components. However, the age of blood has not been shown to confer differences in pulmonary, immunologic, or hemostatic function in those who receive fresh vs standard issue blood.<sup>86,87</sup> A male-predominant plasma strategy also failed to reduce the possible TRALI incidence.<sup>1,18</sup> Given similarities in the pathophysiology and clinical outcomes between possible TRALI and

ARDS, some investigators have proposed renaming possible TRALI as “transfused ARDS.”<sup>1,83</sup> A working group is reconsidering the nomenclature for possible TRALI given confusion regarding adverse event reporting and donor deferral as well as to allow additional characterization of its epidemiology.

### TACO


The pathophysiology of TACO resembles that of other forms of acute cardiogenic pulmonary edema.<sup>88</sup> In healthy individuals, pulmonary capillary pressures are counterbalanced by colloid osmotic pressure, and small volumes of transudate are removed from alveoli by the pulmonary lymphatic system. The latter is able to adapt to a range of left atrial and pulmonary capillary pressures, thus maintaining homeostasis.<sup>89</sup> Blood transfusion can rapidly increase left atrial and pulmonary capillary pressures, resulting in transudation of fluid into the pulmonary interstitium and alveolar space (ie, TACO). Blood transfusion is thought to increase oncotic and pulmonary capillary pressures more significantly than an equivalent volume of intravenous crystalloid fluid, potentially accounting for its designation from other mechanisms of circulatory overload.<sup>90,91</sup> However, similar to other mechanisms, TACO frequently occurs in patients with preexisting cardiac (left ventricular systolic or diastolic) dysfunction or renal impairment who are unable to compensate for an increase in circulating blood volumes.<sup>2</sup> In these chronic conditions, pulmonary capillary wedge pressures may be persistently elevated with expansion of lymphatic capacity and result in pulmonary edema when further increased with transfusion.

A number of TACO cases occur after a single-blood component transfusion without overt signs of systemic volume overload.<sup>9,32</sup> In these cases, TACO can be accompanied by an acute hypertensive response, where a rapid rise in systemic vascular resistance results in increased cardiac filling pressures and hydrostatic pulmonary edema. It has been hypothesized that BRMs, such as plasma free hemoglobin or nitric oxide scavengers, act on vascular smooth muscle in these cases and contribute to TACO by increasing systemic vascular resistance.<sup>92-94</sup> Countering this hypothesis is evidence that prolonged storage of blood, in which BRMs are known to accumulate, does not result in differences in pulmonary function in transfused cardiac surgery or intensive care patients.<sup>86,95,96</sup>

The role for recipient inflammation in the pathogenesis of TACO remains an area of debate. Case series have shown that a systemic inflammatory response, including fevers, occurs in some patients with TACO. However, case-control studies have shown elevations in the inflammatory cytokine IL-8 before transfusion in patients who develop TRALI and possible TRALI but not in those who develop TACO.<sup>1,21,63</sup> In addition, a combination of inflammatory cytokines was shown to be useful in differentiating TACO from TRALI and possible TRALI after transfusion.<sup>20</sup> Laboratory investigations and clinical trials are needed to control for confounding factors for inflammation, such as recent surgery, which are frequently associated with TACO.

### Mitigation

Despite underestimation of incidence, passive hemovigilance reporting mechanisms complement active surveillance studies through provision of data on trends related to mitigation strategies.<sup>55,97-100</sup> In 2007, the American Red Cross began to distribute plasma, preferentially from male donors to limit exposure to donor leukocyte antibodies from previously pregnant female blood donors. Subsequently, the investigators observed an 80% reduction in the passively reported rate of TRALI related to plasma transfusion.<sup>97</sup> After the adoption of male-



**Figure 1.** TRALI cases by blood component type after implementation of a male donor plasma mitigation strategy. TRALI cases classified in the American Red Cross hemovigilance program are expressed per million distributed components for transfusions involving only a single component type. The black stacked bars are reported fatalities. Lines show 95% confidence intervals (95% CIs) for the overall TRALI rates (fatal and nonfatal cases). OR, odds ratio; PLT, platelet. Reprinted from Eder et al<sup>104</sup> with permission.

only plasma collection, the epidemiology of TRALI shifted toward RBC and platelet blood components (Figure 1).<sup>101</sup> Due to transfusion of a much larger number of RBCs compared with platelets and plasma, the majority of TRALI cases are associated with red cell units. However, the per component rate of TRALI reported to the American Red Cross after plasma mitigation was higher for apheresis platelets, which contain large volumes of donor plasma, than for RBCs or male donor–predominant plasma. In addition, the rate of TRALI was ~6-fold higher with female compared with male apheresis platelet donors.

Concern that the current platelet supply would not be sufficient to support conversion to male-only donations led to a strategy to screen female apheresis platelet donors for leukocyte antibodies. In 2009, the National Health Service Blood and Transplant in the United Kingdom began to test female apheresis platelet donors and defer those positive for HLA class 1 and/or class 2 antibodies. Over a 1-year period, this policy identified higher-risk antibody-positive donors, and when combined with other measures, it further reduced TRALI incidence.<sup>102</sup> More recently, one blood center reported that platelet mitigation strategies had reduced TRALI incidence related to platelet transfusion nearly 3-fold.<sup>103</sup>

In 2009, the vast majority of US blood centers surveyed had initiated some measures of screening for high-risk platelet donors in response to an AABB (formerly American Association of Blood Banks) bulletin recommending platelet and plasma mitigation strategies.<sup>11</sup> In October 2016, the AABB issued an updated standard now requiring blood centers to distribute apheresis platelets exclusively collected from males, females who have never been pregnant, or females with negative HLA antibody test results since their most recent pregnancy. One estimate suggested that a strategy to test all previously pregnant female plateletpheresis donors for HLA antibodies could further reduce the risk of TRALI related to platelet transfusion by 60%.<sup>101</sup> However, data on the impact of universal platelet mitigation on reduction in TRALI incidence in the United States are not yet available.

Although mitigation strategies have been successful in reducing the risk of TRALI, they do revisit the challenges of maintaining an adequate blood supply. One study found that the residual risk of TRALI from plasma transfusion was confined almost entirely to group AB female donors.<sup>104</sup> The latter are universally compatible plasma donors, and they are in short supply but high demand. Although the majority of group AB plasma components were from male donors, 40% were from female donors unscreened for HLA antibodies and therefore, had an associated increased risk for TRALI. Recent data supporting the safety of group A plasma in trauma situations rather than ABO-compatible group AB plasma may decrease the need for collection of female plasma due to blood supply limitations.<sup>105</sup>

Additional prevention of TACO and TRALI requires identification and mitigation of modifiable risk factors. The risk related to plasma is ascribed, in part, to emergency transfusion with unscreened AB plasma in the case of TRALI and large infused volumes in individuals with impaired cardiac and renal function in the case of TACO. In the case of TACO, slowing of blood infusion rates and prophylactic volume reduction with diuretics may benefit selected patients.<sup>8,121</sup> The use of homeostatic agents, such as factor concentrates, prothrombin complex concentrates, and antithrombotics, may be an alternative to emergency plasma transfusion, and a factor concentrate was less frequently associated with pulmonary edema compared with plasma in a small clinical trial of patients receiving anticoagulation.<sup>122</sup>

Pooling of products and the use of additive solutions seem to be other practical ways to reduce the risk of TRALI from blood components. In the case of pooling, platelet and plasma components are prepared from multiple donors; this may dilute any leukocyte antibodies or neutralize any antibodies by residual leukocytes or soluble HLA or HNA antigens in the pool. For solvent/detergent plasma products, plasma from up to 2500 blood donors is pooled and treated with solvent 1% tri-*N*-butylphosphate and detergent 1% Triton X-100, resulting in lower antibody titers or antibody neutralization. Observational studies of solvent/detergent plasma suggest a significant reduction in the risk of TRALI.<sup>98,123,124</sup> Some platelet additive solutions replace ~2/3 of the plasma contained in the platelet component and have been associated with a decline in TRALI incidence in buffy coat-derived platelet concentrates.<sup>125</sup>

In addition to mitigation strategies, the widespread adoption of PBM has played a significant role in reducing the incidence of both TACO and TRALI. The number of units transfused is a risk factor for all pulmonary transfusion reactions, and reduction in transfusion is a core tenet of PBM. PBM strategies are derived from randomized control trial data that support the safety of restrictive transfusion practice in both medical and surgical populations.<sup>106-109</sup> A meta-analysis of clinical trials suggested that restrictive transfusion resulted in a lower incidence of posttransfusion pulmonary edema compared with liberal transfusion.<sup>110</sup> In a randomized pilot study of patients with leukemia, restrictive RBC transfusion was also not associated with differences in neutropenic fever or bleeding complications.<sup>111</sup> PBM strategies have led to a substantial decline in blood transfusion in many developed countries over the past 5 years.<sup>112-120</sup> In parallel with reduction in blood transfusion, recent active surveillance studies of TACO and TRALI found lower incidence rates of transfusion-related adverse events.<sup>5,9</sup>

### Future directions


Significant progress has been made in both the understanding of TRALI and its mitigation. Future strategies for the prevention of TRALI may include immune-based strategies to block donor antibodies or the

immune response to transfused antibodies. Human investigations have found increased plasma levels of the inflammatory cytokine IL-8 but lower levels of the anti-inflammatory cytokine IL-10 in both antibody- and nonantibody-mediated cases of TRALI compared with those of possible TRALI.<sup>1,20,126</sup> Recently, it was shown that regulatory T cells and dendritic cells were protective in a murine model of antibody-mediated TRALI, and this protection was associated with increased plasma levels of IL-10.<sup>127</sup> In addition, there was evidence of a benefit of IL-10 administration in the prevention of murine TRALI as well as treatment after its induction with HLA antibodies (Figure 2). These findings may indicate a distinct mechanism of pathogenesis in TRALI compared with other forms of lung injury as well as opportunities for prevention and treatment.

Prior studies have suggested a lack of benefit of the anti-inflammatory effects of systemic corticosteroids in ARDS and a lipopolysaccharide-stimulated murine model of TRALI.<sup>60,128</sup> Differences in murine TRALI models or the timing of corticosteroid administration may explain these disparate effects. Other anti-inflammatory modalities to prevent or treat TRALI have also been proposed, including the targeting of C-reactive protein, IL-8, reactive oxidative species, neutrophil extracellular traps, or Fc receptors.<sup>129</sup> Additional investigations are needed to confirm that these murine model findings parallel human pathophysiology before embarking on clinical studies of TRALI prevention or treatment. The recognition that any immunomodulatory therapy could increase the risk of infection is especially relevant in immunocompromised patients (eg, those with hematologic malignancies). In contrast to TRALI, few *in vitro* or *in vivo* investigations have been conducted to further understand the pathogenesis of TACO. *In vivo* models of TACO are needed to study the effect of individual blood components relative to other intravenous fluids on pulmonary capillary pressures, specific rates of blood administration, and the benefit of prophylactic diuretics as well as the role of systemic inflammation.

Work to improve blood collection and storage may also provide the opportunity to prevent TACO and TRALI. Modifications to blood components include the development of novel filters, apheresis collection systems, pathogen reduction, extended storage of platelets, and new methods of leukodepletion or irradiation. A novel prestorage filter absorbed HLA antibodies and lipids in addition to leukocytes and platelets, and it was associated with reduced neutrophil activation and TRALI incidence in an animal model.<sup>130</sup> Translation of an effective filter to clinical practice could obviate the need for specific donor mitigation strategies. Continued research to develop RBC and platelet storage solutions that preserve blood product quality but also mitigate TRALI also hold promise.<sup>131-134</sup> In addition, an ongoing randomized clinical trial is revisiting the potential benefit of washing allogeneic RBCs in reducing the incidence of TACO and TRALI.<sup>92,135</sup>

At a systems level, prevention of TACO and TRALI requires implementation science research to harness the ever-expanding role of EHRs in medical care. The application of natural language processing or machine learning methods to EHR data of transfusion recipients would allow for more widespread surveillance and sophisticated approaches to adverse event reporting for blood and blood-derived products. Automated identification of adverse events utilizing large sources of blood donor, component, and transfusion recipient data would allow assessment of the safety of blood component modifications (eg, pathogen-reduced products or extended storage of platelets) in addition to additional mitigation strategies. Expanded active surveillance of pulmonary transfusion reactions would also serve to aid in the



**Figure 2.** TRALI suppression in CD4+ T cell-depleted mice with murine IL-10 administration. (A) Decreased lung wet/dry (W/D) weight ratios of CD4+ T cell-depleted C57BL/6 mice infused with 34-1-2s/AF6-88.5.5.3 and treated prophylactically with murine IL-10 administration (45 mg/kg intravenously). (B) Lung W/D weight ratios of CD4+ T cell-depleted C57BL/6 mice infused with 34-1-2s/AF6-88.5.5.3 and treated therapeutically 15 minutes later with or without murine IL-10 administration (45 mg/kg intravenously) after onset of TRALI (at least a 2° drop in rectal temperature 10 minutes after TRALI antibody injection). Comparisons in both panels were analyzed with one-tailed unpaired *t* test. Each dot represents 1 mouse, and error bars represent standard deviation. \**P* < .05; \*\*\*\**P* < .0001. PBS, phosphate-buffered saline. Reprinted from Kapur et al<sup>127</sup> with permission.

refinement of current diagnostic criteria for TACO and TRALI, allowing better discrimination of individual reactions from other causes of pulmonary edema.

Predictive algorithms could also be embedded within the EHR to allow for real-time identification of patients at increased risk of an adverse pulmonary transfusion event. For example, clinical decision support systems incorporating hemodynamic parameters or creatinine clearance could trigger recommendations for diuretic administration or alternatives to transfusion in patients at risk for TACO.

Evidence of a systemic inflammatory response or other recipient risk factors could trigger allocation of lower-risk platelet or plasma units to hospitalized patients at increased risk for TRALI. Real-time identification of at-risk individuals could also be coupled to clinical trials of immune-based therapies for TRALI. Continued collaboration by bench and clinical researchers, clinicians, epidemiologists, and blood donor centers will be required to further understand and minimize these severe complications of blood transfusion.

## Correspondence

Nareg Roubinian, Blood Systems Research Institute, 270 Masonic Ave, San Francisco, CA 94118; e-mail: nroubinian@bloodsystems.org.

## References

1. Toy P, Gajic O, Bacchetti P, et al; TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. *Blood*. 2012;119(7):1757-1767.
2. Murphy EL, Kwaan N, Looney MR, et al; TRALI Study Group. Risk factors and outcomes in transfusion-associated circulatory overload. *Am J Med*. 2013;126(4):357.e29-357.e38.
3. Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. *Transfusion*. 2011;51(2):338-343.
4. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. *Am J Respir Crit Care Med*. 2007;176(9):886-891.
5. Clifford L, Jia Q, Yadav H, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. *Anesthesiology*. 2015;122(1):21-28.
6. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion*. 2004;44(12):1774-1789.
7. Fatalities reported to FDA following blood collection and transfusion 2016. Available at <https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf>. Accessed 16 November 2018.
8. Clifford L, Jia Q, Subramanian A, Yadav H, Schroeder DR, Kor DJ. Risk factors and clinical outcomes associated with perioperative transfusion-associated circulatory overload. *Anesthesiology*. 2017;126(3):409-418.
9. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Contemporary risk factors and outcomes of transfusion-associated circulatory overload. *Crit Care Med*. 2018;46(4):577-585.
10. Bolton-Maggs PHB. Serious hazards of transfusion—conference report: celebration of 20 years of UK haemovigilance. *Transfus Med*. 2017;27(6):393-400.
11. Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. *Transfusion*. 2010;50(6):1312-1321.
12. Hendrickson JE, Roubinian NH, Chowdhury D, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study (REDS-III). Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. *Transfusion*. 2016;56(10):2587-2596.
13. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Incidence and clinical characteristics of transfusion-associated circulatory overload using an active surveillance algorithm. *Vox Sang*. 2017;112(1):56-63.
14. Goldman M, Weibert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA; TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev*. 2005;19(1):2-31.
15. Goldman M, Land K, Robillard P, Wiersum-Osselton J. Development of standard definitions for surveillance of complications related to blood donation. *Vox Sang*. 2016;110(2):185-188.
16. AuBuchon JP, Fung M, Whitaker B, Malasky J. AABB validation study of the CDC's National Healthcare Safety Network Hemovigilance

- Module adverse events definitions protocol. *Transfusion*. 2014;54(8):2077-2083.
17. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. *Crit Care Med*. 2006;34(suppl 5):S109-S113.
  18. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of postoperative transfusion-related acute lung injury. *Anesthesiology*. 2015;122(1):12-20.
  19. Rana R, Fernández-Pérez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. *Transfusion*. 2006;46(9):1478-1483.
  20. Roubinian NH, Looney MR, Kor DJ, et al; TRALI Study Group. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions. *Transfusion*. 2015;55(8):1838-1846.
  21. Looney MR, Roubinian N, Gajic O, et al; Transfusion-Related Acute Lung Injury Study Group. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury\*. *Crit Care Med*. 2014;42(7):1676-1687.
  22. Toy P, Bacchetti P, Grimes B, et al. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. *Transfusion*. 2015;55(5):947-952.
  23. Legrand M, Gayat E. Novelities in biomarkers for the management of circulatory failure. *Curr Opin Crit Care*. 2013;19(5):410-416.
  24. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*. 2002;347(3):161-167.
  25. Semler MW, Marney AM, Rice TW, et al; NIH NHLBI ARDS Network. B-type natriuretic peptide, aldosterone, and fluid management in ARDS. *Chest*. 2016;150(1):102-111.
  26. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med*. 2006;354(21):2213-2224.
  27. Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. *Transfusion*. 2005;45(7):1056-1063.
  28. Tobian AA, Sokoll LJ, Tisch DJ, Ness PM, Shan H. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. *Transfusion*. 2008;48(6):1143-1150.
  29. Li G, Daniels CE, Kojic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. *Transfusion*. 2009;49(1):13-20.
  30. Roubinian NH, Looney MR, Keating S, et al; TRALI Study Group. Differentiating pulmonary transfusion reactions using recipient and transfusion factors. *Transfusion*. 2017;57(7):1684-1690.
  31. Clifford L, Singh A, Wilson GA, et al. Electronic health record surveillance algorithms facilitate the detection of transfusion-related pulmonary complications. *Transfusion*. 2013;53(6):1205-1216.
  32. Lieberman L, Maskens C, Cserti-Gazdewich C, et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. *Transfus Med Rev*. 2013;27(4):206-212.
  33. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. *JAMA*. 1994;271(16):1276-1280.
  34. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. *Transfusion*. 2010;50(1):213-220.
  35. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. *Transfusion*. 2007;47(4):599-607.
  36. Middelburg RA, Van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury: a case-referent study from the International TRALI Unisex Research Group. *Transfusion*. 2010;50(11):2447-2454.
  37. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. *Crit Care Med*. 2007;35(7):1645-1648.
  38. Kleinman SH, Triulzi DJ, Murphy EL, et al; National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components. *Transfusion*. 2011;51(10):2078-2091.
  39. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. *Transfusion*. 2009;49(9):1825-1835.
  40. Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. *Transfusion*. 2003;43(12):1683-1686.
  41. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. *Transfusion*. 2001;41(2):264-268.
  42. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. *Blood*. 2003;101(2):454-462.
  43. Strait RT, Hicks W, Barasa N, et al. MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. *J Exp Med*. 2011;208(12):2525-2544.
  44. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. *JAMA*. 2002;287(15):1968-1971.
  45. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. *Anesth Analg*. 2009;108(3):759-769.
  46. Finlay HE, Cassorla L, Feiner J, Toy P. Designing and testing a computer-based screening system for transfusion-related acute lung injury. *Am J Clin Pathol*. 2005;124(4):601-609.
  47. Vlaar AP, Binnekade JM, Prins D, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. *Crit Care Med*. 2010;38(3):771-778.
  48. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. *Transfusion*. 2012;52(1):160-165.
  49. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. *Blood*. 2007;109(4):1752-1755.
  50. Looney MR, Matthay MA. Animal models of transfusion-related acute lung injury. *Crit Care Med*. 2006;34(suppl 5):S132-S136.
  51. Sachs UJ, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. *Blood*. 2006;107(3):1217-1219.
  52. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. *Transfusion*. 1985;25(6):573-577.
  53. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. *Transfusion*. 2001;41(10):1244-1248.
  54. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. *Transfusion*. 2004;44(12):1683-1688.
  55. Chapman CE, Stainsby D, Jones H, et al; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. *Transfusion*. 2009;49(3):440-452.
  56. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. *Vox Sang*. 2008;95(4):313-317.
  57. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. *Transfus Med Rev*. 2009;23(4):266-283.
  58. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. *Chest*. 2004;126(1):249-258.



59. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. *Am J Physiol Cell Physiol*. 2002; 283(6):C1592-C1603.
60. Müller MC, Tuinman PR, van der Sluijs KF, et al. Methylprednisolone fails to attenuate lung injury in a mouse model of transfusion related acute lung injury. *Transfusion*. 2014;54(4):996-1001.
61. Kapur R, Kim M, Rondina MT, Porcelijn L, Semple JW. Elevation of C-reactive protein levels in patients with transfusion-related acute lung injury. *Oncotarget*. 2016;7(47):78048-78054.
62. Kapur R, Kim M, Shanmugabhavanathan S, Liu J, Li Y, Semple JW. C-reactive protein enhances murine antibody-mediated transfusion-related acute lung injury. *Blood*. 2015;126(25):2747-2751.
63. Vlaar AP, Hofstra JJ, Determann RM, et al. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control study. *Crit Care Med*. 2012;40(10):2813-2820.
64. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. *J Clin Invest*. 2012;122(7):2661-2671.
65. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. *Blood*. 2012;119(26):6335-6343.
66. Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA class II antibodies in TRALI. *Transfusion*. 2003;43(2):185-191.
67. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. *J Clin Invest*. 2006;116(6):1615-1623.
68. Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A. Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. *Br J Haematol*. 1996;93(3):707-713.
69. Hechler B, Maître B, Magnenat S, et al. Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. *J Thromb Haemost*. 2016;14(6):1255-1267.
70. McKenzie CG, Kim M, Singh TK, Milev Y, Freedman J, Semple JW. Peripheral blood monocyte-derived chemokine blockade prevents murine transfusion-related acute lung injury (TRALI). *Blood*. 2014; 123(22):3496-3503.
71. Middelburg RA, van Stein D, Briët E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. *Transfusion*. 2008;48(10):2167-2176.
72. van Stein D, Beckers EA, Peters AL, et al. Underdiagnosing of antibody-mediated transfusion-related acute lung injury: evaluation of cellular-based versus bead-based techniques. *Vox Sang*. 2016;111(1):71-78.
73. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. *Transfusion*. 2010;50(12):2738-2744.
74. Watkins TR, Rubenfeld GD, Martin TR, et al. Effects of leukoreduced blood on acute lung injury after trauma: a randomized controlled trial. *Crit Care Med*. 2008;36(5):1493-1499.
75. Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. *Blood*. 2011;117(16):4218-4225.
76. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. *J Clin Invest*. 1998;101(7):1458-1467.
77. Tuinman PR, Gerards MC, Jongsma G, Vlaar AP, Boon L, Juffermans NP. Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. *Clin Exp Immunol*. 2011;165(2):278-284.
78. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. *Blood*. 2006;108(7):2455-2462.
79. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. *Transfusion*. 1997;37(7): 719-726.
80. Silliman CC, Moore EE, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. *Transfusion*. 2011;51(12):2549-2554.
81. Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. *Blood Rev*. 2015;29(1):51-61.
82. Peters AL, Vervaart MA, van Bruggen R, et al. Non-polar lipids accumulate during storage of transfusion products and do not contribute to the onset of transfusion-related acute lung injury. *Vox Sang*. 2017;112(1): 25-32.
83. Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. *Transfusion*. 2017;57(3):709-713.
84. Seong GM, Lee Y, Hong SB, Lim CM, Koh Y, Huh JW. Prognosis of acute respiratory distress syndrome in patients with hematological malignancies [published online ahead of print 1 January 2018]. *J Intensive Care Med*. doi:10.1177/0885066617753566.
85. Türkoğlu M, Erdem GU, Suyun E, et al. Acute respiratory distress syndrome in patients with hematological malignancies. *Hematology*. 2013;18(3):123-130.
86. Kor DJ, Kashyap R, Weiskopf RB, et al. Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial. *Am J Respir Crit Care Med*. 2012;185(8): 842-850.
87. Weiskopf RB, Feiner J, Toy P, et al. Fresh and stored red blood cell transfusion equivalently induce subclinical pulmonary gas exchange deficit in normal humans. *Anesth Analg*. 2012;114(3):511-519.
88. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. *N Engl J Med*. 2005;353(26):2788-2796.
89. Gropper MA, Wiener-Kronish JP, Hashimoto S. Acute cardiogenic pulmonary edema. *Clin Chest Med*. 1994;15(3):501-515.
90. Gupta SP, Nand N, Gupta MS. Left ventricular filling pressures after rapid blood transfusion in cases of chronic severe anemia. *Angiology*. 1982;33(5):343-348.
91. Nand N, Gupta MS, Sharma M. Effect of different amounts of blood transfusion given at different speeds on left ventricular filling pressure in cases of chronic severe anemia. *Angiology*. 1986;37(4):281-284.
92. Warner MA, Welsby IJ, Norris PJ, et al. Point-of-care washing of allogeneic red blood cells for the prevention of transfusion-related respiratory complications (WAR-PRC): a protocol for a multicenter randomised clinical trial in patients undergoing cardiac surgery. *BMJ Open*. 2017;7(8):e016398.
93. Donadee C, Raat NJ, Kanas T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. *Circulation*. 2011;124(4):465-476.
94. Risbano MG, Kanas T, Triulzi D, et al. Effects of aged stored autologous red blood cells on human endothelial function. *Am J Respir Crit Care Med*. 2015;192(10):1223-1233.
95. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. *N Engl J Med*. 2015; 372(15):1419-1429.
96. Lacroix J, Hébert PC, Fergusson DA, et al; Canadian Critical Care Trials Group. Age of transfused blood in critically ill adults. *N Engl J Med*. 2015;372(15):1410-1418.
97. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). *Transfusion*. 2010; 50(8):1732-1742.
98. Ozier Y, Muller JY, Mertes PM, et al. Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008. *Transfusion*. 2011;51(10):2102-2110.

99. Jutzi M, Levy G, Taleghani BM. Swiss haemovigilance data and implementation of measures for the prevention of transfusion associated acute lung injury (TRALI). *Transfus Med Hemother*. 2008;35(2):98-101.
100. Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. *Transfusion*. 2012;52(3):567-574.
101. Eder AF, Dy BA, O'Neill EM. Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusion-related acute lung injury risk from apheresis platelets. *Transfusion*. 2016;56(6 pt 2):1608-1615.
102. Lucas G, Win N, Calvert A, et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. *Vox Sang*. 2012;103(1):10-17.
103. Shaz BH. Bye-bye TRALI: by understanding and innovation. *Blood*. 2014;123(22):3374-3376.
104. Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ. The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. *Transfusion*. 2013;53(7):1442-1449.
105. Dunbar NM, Yazer MH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators. Safety of the use of group A plasma in trauma: the STAT study. *Transfusion*. 2017;57(8):1879-1884.
106. Waters JH, Ness PM. Patient blood management: a growing challenge and opportunity. *Transfusion*. 2011;51(5):902-903.
107. Shander A, Bracey AW Jr, Goodnough LT, et al. Patient blood management as standard of care. *Anesth Analg*. 2016;123(4):1051-1053.
108. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. *JAMA*. 2016;316(19):2025-2035.
109. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*. 2016;10:CD002042.
110. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. *Am J Med*. 2014;127(2):124-131.e3.
111. DeZern AE, Williams K, Zahurak M, et al. Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. *Transfusion*. 2016;56(7):1750-1757.
112. Roubinian NH, Escobar GJ, Liu V, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III). Trends in red blood cell transfusion and 30-day mortality among hospitalized patients. *Transfusion*. 2014;54(10 pt 2):2678-2686.
113. Roubinian NH, Escobar GJ, Liu V, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III). Decreased red blood cell use and mortality in hospitalized patients. *JAMA Intern Med*. 2014;174(8):1405-1407.
114. Mazzeffi MA, See JM, Williams B, et al. Five-year trends in perioperative red blood cell transfusion from index cases in five surgical specialties: 2011 to 2015. *Transfusion*. 2018;58(5):1271-1278.
115. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. *Transfusion*. 2017;57(suppl 2):1588-1598.
116. Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United States blood collection and transfusion: results from the 2013 AABB Blood Collection, Utilization, and Patient Blood Management Survey. *Transfusion*. 2016;56(9):2173-2183.
117. Shehata N, Forster A, Lawrence N, et al. Changing trends in blood transfusion: an analysis of 244,013 hospitalizations. *Transfusion*. 2014;54(10 pt 2):2631-2639.
118. Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP; Northern Regional Transfusion Committee. Ten-year pattern of red blood cell use in the North of England. *Transfusion*. 2013;53(3):483-489.
119. Freedman J. The ONTraC Ontario program in blood conservation. *Transfus Apheresis Sci*. 2014;50(1):32-36.
120. Meybohm P, Herrmann E, Steinbicker AU, et al; PBM-study Collaborators. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient's outcome: a prospective, multicenter cohort study with a noninferiority design. *Ann Surg*. 2016;264(2):203-211.
121. Roubinian N, Murphy EL. Adjusting the focus on transfusion-associated circulatory overload. *Anesthesiology*. 2017;126(3):363-365.
122. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. *Circulation*. 2013;128(11):1234-1243.
123. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. *Transfusion*. 2005;45(10):1628-1631.
124. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. *Vox Sang*. 2003;85(2):88-95.
125. Andreu G, Boudjedir K, Muller JY, et al. Analysis of transfusion-related acute lung injury and possible transfusion-related acute lung injury reported to the french hemovigilance network from 2007 to 2013. *Transfus Med Rev*. 2018;32(1):16-27.
126. Kapur R, Kim M, Rebetz J, Rondina MT, Porcelijn L, Semple JW. Low levels of interleukin-10 in patients with transfusion-related acute lung injury. *Ann Transl Med*. 2017;5(16):339.
127. Kapur R, Kim M, Aslam R, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. *Blood*. 2017;129(18):2557-2569.
128. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. *BMJ*. 2008;336(7651):1006-1009.
129. Semple JW, McVey MJ, Kim M, Rebetz J, Kuebler WM, Kapur R. Targeting transfusion-related acute lung injury: the journey from basic science to novel therapies. *Crit Care Med*. 2018;46(5):e452-e458.
130. Silliman CC, Kelher MR, Khan SY, et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo. *Blood*. 2014;123(22):3488-3495.
131. Acker JP, Marks DC, Sheffield WP. Quality assessment of established and emerging blood components for transfusion. *J Blood Transfus*. 2016;2016:4860284.
132. Podlosky L, Poirier A, Nahiriak S, Clarke G, Acker JP. Viability of AS-3 and SAG-M red cells stored in plastic syringes for pediatric transfusion. *Transfusion*. 2008;48(7):1300-1307.
133. Spinella PC, Acker J. Storage duration and other measures of quality of red blood cells for transfusion. *JAMA*. 2015;314(23):2509-2510.
134. Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on red cell post-transfusion outcomes. *Transfus Med Rev*. 2018;32(1):28-35.
135. Bennett-Guerrero E, Kirby BS, Zhu H, Herman AE, Bandarenko N, McMahon TJ. Randomized study of washing 40- to 42-day-stored red blood cells. *Transfusion*. 2014;54(10):2544-2552.